Key facts
- BrainEver’s last known valuation is $37.6M (Sep 2024).
- It has raised $67.1M; the latest was Later Stage VC ($38.1M) in Jul 2025.
- Notable investors include Bpifrance, European Innovation Council, Turenne Groupe, Entropia Capital, Critical Path Capital — 10 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 10 names
- ·Watchlist + deal alerts for BrainEver
- ·The full record, as it builds
Funding rounds
No funding rounds for BrainEver are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About BrainEver
Operator of a medical research agency intended to develop drugs for the treatment of neurodegenerative disorders. The company's services specialize in the research and development of novel therapeutics using specific proprietary proteins to treat Parkinson's, amyotrophic lateral sclerosis, and Huntington's diseases, enabling healthcare practitioners to avail of drugs while providing the required treatment efficiently.
- Sector
- Healthcare
- HQ
- Paris, France
- Founded
- 2015
- Employees
- 17
- Website
- brainever.fr/
- Ownership
- Privately Held (backing)
BrainEver doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in BrainEver shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on BrainEver in its N-PORT filings yet. We sweep new filings monthly.